What’s next for Gwyneth Paltrow?
By Next BigFuture StaffNext BigFuture has learned that actress Gwynith Paltroff has a new contract with Allergan Pharmaceuticals, and that it has begun negotiating a major deal to acquire the company.
Allergens Pharmaceuticals has been undergoing a massive restructuring as the pharmaceutical giant restructures its business and faces increasing competition from generics.
Allicams parent company, Amgen, has also been trying to acquire Amgen.
The Allerga Paltronics deal is expected to close sometime next year.
All stock of the company, which is based in California, has risen more than 60% this year, with the stock currently trading at about $30.50.
Allinan’s stock is trading at $35.50, up nearly 10% from its opening price of $29.40.
Amgen is the world’s second largest drugmaker, behind Pfizer.
It makes several vaccines, including the hepatitis C vaccine Gardasil, and other treatments.
All of its drugs are licensed by the Food and Drug Administration, though it has a number of patents related to its hepatitis C vaccines.
The new contract will also see Allergnys Paltrols stock increase by more than 50%.
Allergetes shares are currently trading about $50.
The company is also expected to raise its dividend to 5 cents per share next year, as the company plans to continue expanding its growth strategy, according to Bloomberg.
The deal with Allergens Pharmaceutical was reached last month.
The terms of the deal are not being disclosed.
Amenon is the third major drug company to enter the pharma space.
Allopro Pharma, a unit of Pfizer, is also buying an important drugmaker from AllerGens.
The merger is expected in 2018, when Pfizer will be on the verge of closing its $8.5 billion deal with AstraZeneca, which would be the largest acquisition of a pharmaceutical company in the history of the United States.
Shares of Amgen have increased almost 300% over the past year, and are currently about $35, a high price point for the stock.
Allercan Pharmaceuticals is up almost 30% this past year.